Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)
Developing PET/SPECT imaging ligands for brain study, utilizing pre-clinical data to advance potential clinical research - CNS Disorders.
Funder: National Institutes of Health
Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | September 7, 2025 (AIDS) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | January 7, 2026 (AIDS) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | May 7, 2026 (AIDS)
Funding Amounts: No budget cap; budgets must reflect actual project needs. Project period up to 5 years.
Summary: Supports development and evaluation of novel PET and SPECT imaging ligands as biomarkers for CNS disorder research and drug discovery, including pilot or clinical feasibility studies.
Key Information: Applicants requesting ≥$500,000 direct costs in any year must contact NIH program staff at least 6 weeks before submission.
Description
This opportunity invites research grant applications for the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in the human brain. The focus is on molecular targets implicated in central nervous system (CNS) disorders, with the goal of advancing these ligands for use as biomarkers in clinical research, drug discovery, and studies of disease pathophysiology. Projects may include pilot or clinical feasibility studies using pre-clinical data.
The program encourages collaborations between academia and industry to accelerate the development and application of PET/SPECT radiotracers for mental health and neurodegenerative disorders. Both pre-clinical and clinical research are supported, and clinical trials are optional.
